Valneva's Chikungunya Vaccine License Suspended by FDA, Shares Drop

TL;DR Summary
The FDA has suspended the biologics license for Ixchiq, a live-attenuated chikungunya vaccine by Valneva, due to serious safety concerns including reports of chikungunya-like illness in some recipients, following its accelerated approval less than two years ago.
- FDA pulls biologics license for chikungunya vaccine statnews.com
- Valneva shares tumble after suspension of US chikungunya vaccine licence Reuters
- Navigating Setbacks: Valneva's IXCHIQ® and the Path to Vaccine Sector Resilience AInvest
- Valneva Shares Plunge After US Halts Chikungunya Vaccine License Bloomberg.com
- Johnson Fistel Investigates Valneva Following FDA Suspension GlobeNewswire
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
1 min
vs 1 min read
Condensed
78%
168 → 37 words
Want the full story? Read the original article
Read on statnews.com